62nd Annual Meeting

October 26 - 31, 2015

Sharon Wigal, PhD

AVIDA Inc.

• Advisory Board: Eli Lilly and Company; Ironshore Inc.; Neos Therapeutics, Inc.; NextWave Pharmaceuticals; Noven Pharmaceuticals, Inc.; Nutec Group; Pfizer Inc.; Rhodes Pharmaceuticals L.P.; Shionogi; Shire; Sunovion Pharmaceuticals Inc.; Tris Pharma, Inc.
• Consultant: Eli Lilly and Company; Ironshore Inc.; Neos Therapeutics, Inc.; NextWave Pharmaceuticals; Noven Pharmaceuticals, Inc.; Nutec Group; Pfizer Inc.; Rhodes Pharmaceuticals L.P.; Shionogi; Shire; Sunovion Pharmaceuticals Inc.; Tris Pharma, Inc.
• Grant Support: Eli Lilly and Company; Forest Laboratories, Inc.; Ironshore Inc.; NextWave Pharmaceuticals; Noven Pharmaceuticals, Inc.; Nutec Group; Purdue Pharma L.P.; Rhodes Pharmaceuticals L.P.; Shire; Sunovion Pharmaceuticals Inc.; Tris Pharma, Inc.
• Research Support: Eli Lilly and Company; Forest Laboratories, Inc.; Ironshore Inc.; NextWave Pharmaceuticals; Noven Pharmaceuticals, Inc.; Nutec Group; Purdue Pharma L.P.; Rhodes Pharmaceuticals L.P.; Shire; Sunovion Pharmaceuticals Inc.; Tris Pharma, Inc.
• Speakers Bureau: Eli Lilly and Company; Ironshore Inc.; Neos Therapeutics, Inc.; NextWave Pharmaceuticals; Noven Pharmaceuticals, Inc.; Pfizer Inc.; Shionogi; Shire; Sunovion Pharmaceuticals Inc.; Tris Pharma, Inc.